National· August 17, 2026 at 04:58 p.m.
Health Canada Approves New Drug for Managing Hot Flashes in Breast Cancer Patients
Key takeaways
- Health Canada has approved Elinzanetant for managing hot flashes in breast cancer patients
- The drug, marketed as Lynkuet, reduces severity and frequency of symptoms
- Approval follows a review process to ensure safety and efficacy
Health Canada has approved Elinzanetant, a drug marketed under the brand name Lynkuet, to alleviate hot flashes and night sweats in breast cancer patients who have entered menopause due to estrogen-suppressing treatment. This approval marks a significant development for managing symptoms in these patients.
